Pharvaris N.V.
NLValuation Metrics
Pharvaris N.V.'s Market Cap is $2.54B. At end of 2025 it was $935M. Ranked #1832 of 3,121 in US market (top 59%), #666 of 1,463 on NASDAQ (top 46%), #111 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.54B | US#1,832/3,121 Sec#111/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-194M | US—/3,121 Sec—/266 |
| Total Assets | $386M | US#2,859/3,121 Sec#193/266 |
| Net Assets | $353M | US#2,451/3,121 Sec#148/266 |
| Employees | 134 | US#2,576/3,121 Sec#157/266 |
| Value | ||
| P/B | 7.19x | US#2,483/3,121 Sec#177/266 |
| FCF Yield | -6.94% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -54.85% | US#2,700/3,121 Sec#163/266 |
| ROA | -50.20% | US#2,988/3,121 Sec#213/266 |
| Financial Health | ||
| Debt Ratio | 9.26% | US#100/3,121 Sec#46/266 |
| Total Debt | $791448.00 | US#2,990/3,121 Sec#246/266 |
| FCF | $-176M | US#2,755/3,121 Sec#197/266 |
| Cash | $374M | US#1,253/3,121 Sec#69/266 |
| Current Ratio | 11.94x | US#211/3,121 Sec#66/266 |
| Performance | ||
| 1Y Return | 48.21% | US#481/3,121 Sec#97/266 |
| 1M Return | 0.28% | US#466/3,121 Sec#48/266 |
| From 52W High | -15.91% | US#901/3,121 Sec#61/266 |
| 1Y MDD | -19.37% | US#660/3,121 Sec#23/266 |
| Trading | ||
| Volume | 524,376 shares | US#1,307/3,121 Sec#142/266 |
| Trading Value | $19M | US#1,368/3,121 Sec#107/266 |
| Per Share | ||
| EPS | $-2.77 | US—/3,121 Sec—/266 |
| BPS | $5.06 | US#2,277/3,121 Sec#128/266 |
Company Info
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.